Artiva Biotherapeutics to Present Positive AlloNK® Data in Sjögren’s Disease Trial

  • Artiva Biotherapeutics will present updated clinical data on AlloNK® (AB-101) in combination with Rituximab for Sjögren’s disease at ISSjD 2026 on October 1, 2026.
  • The oral presentation will highlight robust efficacy responses in 11 patients with Sjögren’s disease.
  • Artiva plans to initiate a Phase 3 registrational trial for AlloNK® in refractory rheumatoid arthritis in the second half of 2026.
  • AlloNK® is an allogeneic, off-the-shelf, non-genetically modified NK cell therapy designed for outpatient administration.

Artiva Biotherapeutics is positioning AlloNK® as a scalable, outpatient-administered cell therapy for autoimmune diseases, aiming to address unmet needs in refractory rheumatoid arthritis and other conditions. The upcoming Phase 3 trial and positive clinical data presentations could solidify its competitive edge in the cell therapy space. The focus on outpatient settings aligns with broader industry trends toward more accessible and cost-effective treatment options.

Clinical Efficacy
How the robust efficacy responses in Sjögren’s disease patients will translate to other B-cell-driven autoimmune diseases.
Regulatory Pathway
Whether the Phase 3 trial initiation and data readout will support a Biologics License Application (BLA) submission.
Market Positioning
The pace at which Artiva can establish AlloNK® as a leading deep B-cell depleting therapy in refractory rheumatoid arthritis.